Max Semler has a diverse background in business development and finance, beginning as an Analyst at Morgan Stanley from 2014 to 2017 and later serving as an Associate at J.P. Morgan for one year. Following this, Max held various leadership roles, including Associate Director of Business Development at Skyhawk Therapeutics from 2018 to 2020 and Executive Director of Business Development at Dragonfly Therapeutics, Inc. from 2018 to 2023. Most recently, Max has been serving as Chief Business Officer at Amber Bio since September 2025, and from 2023 to 2024, held the position of Vice President of Corporate Development & Strategy at Addition Therapeutics. Max holds a degree in Neuroscience Philosophy from Duke University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices